Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum

No definition available.

Name:	cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum
Namespace Prefix:	cpix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Receivable

+ References

No definition available.

+ Details

Name:	cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable
Namespace Prefix:	cpix_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Collaborative Arrangement, Rights and Obligations, Term

+ References

No definition available.

+ Details

Name:	cpix_CollaborativeArrangementRightsAndObligationsTerm
Namespace Prefix:	cpix_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

- Definition

Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent

+ References

No definition available.

+ Details

Name:	cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent
Namespace Prefix:	cpix_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 30
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355

+ Details

Name:	us-gaap_GainContingencyUnrecordedAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherCommitmentsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=cpix_KyowaKirinMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	cpix_CollaborativeArrangementMilestonePaymentThresholdAxis=cpix_Within30DaysOfFirstSNDAFilingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	cpix_CollaborativeArrangementMilestonePaymentThresholdAxis=cpix_FollowingApprovalOfFirstSNDAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies (Details) - Collaborative Arrangement, Transaction with Party to Collaborative Arrangement - USD ($) $ in Thousands	Dec. 31, 2022	Nov. 07, 2022	Feb. 02, 2022	Jan. 03, 2022
Kyowa Kirin
Other Commitments [Line Items]
Milestone payments, maximum	$ 3,500			$ 3,500
Collaborative arrangement, term	10 years
Kyowa Kirin \| Minimum
Other Commitments [Line Items]
Tiered royalty, percent	5.00%
Kyowa Kirin \| Maximum
Other Commitments [Line Items]
Tiered royalty, percent	10.00%			10.00%
Melinta Therapeutics, LLC and Targanta Therapeutics Corporation
Other Commitments [Line Items]
Sales milestone payments, receivable		$ 1,000
Gain contingency, unrecorded amount		$ 1,000
Melinta Therapeutics, LLC and Targanta Therapeutics Corporation \| Within 30 Days Of First sNDA Filing
Other Commitments [Line Items]
Sales milestone payments, receivable			$ 500
Melinta Therapeutics, LLC and Targanta Therapeutics Corporation \| Following Approval Of First sNDA
Other Commitments [Line Items]
Sales milestone payments, receivable			$ 500